Annick Desjardins

Also affiliated with Duke Medical Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial”.

Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial

The Lancet Child & Adolescent Health(2023)10.1016/s2352-4642(23)00031-7

N/A

1.2DataRank · unranked

48 citations

Daniel Landi, Michael C. Brown, Henry S. Friedman, Roger E. McLendon, James E. Herndon +15 more

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

Science Translational Medicine(2023)10.1126/scitranslmed.abn5649

N/A

0.853DataRank · unranked

30 citations

Charlotte McDowall, Luis Sánchez-Pérez, Cristina Osorio, Patrick C. Duncker, Aaron Briley +15 more

Correcting the drug development paradigm for glioblastoma requires serial tissue sampling

Nature Medicine(2023)10.1038/s41591-023-02464-8

N/A

0.604DataRank · unranked

55 citations

Kelly Hotchkiss, Ian F. Parney, John de Groot, Solmaz Sahebjam, Nader Sanai +31 more

Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

Neuro-Oncology(2025)10.1093/neuonc/noaf118

N/A

0.411DataRank · unranked

8 citations

Michael A. Vogelbaum, Timothy F. Cloughesy, Norbert Galldiks, Nathalie L. Albert, Joerg-Christian Tonn +30 more

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e14015

N/A

0.360DataRank · unranked

10 citations

Vidyalakshmi Chandramohan, Daniel Landi, Margaret Johnson, Mustafa Khasraw, Katherine B. Peters +12 more

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2566

N/A

0.269DataRank · unranked

5 citations

Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret Johnson, Stevie Threatt +10 more

Data from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2023)10.1158/1078-0432.c.6516909

N/A

0DataRank · unranked

0 citations

David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich +9 more